121 related articles for article (PubMed ID: 38189590)
21. Establishment of using serum YKL-40 and SCCA in combination for the diagnosis of patients with esophageal squamous cell carcinoma.
Zheng X; Xing S; Liu XM; Liu W; Liu D; Chi PD; Chen H; Dai SQ; Zhong Q; Zeng MS; Liu WL
BMC Cancer; 2014 Jul; 14():490. PubMed ID: 25001061
[TBL] [Abstract][Full Text] [Related]
22. Cytokeratin 19 fragment CYFRA 21-1 compared with carcinoembryonic antigen, squamous cell carcinoma antigen and neuron-specific enolase in lung cancer. Results of an international multicentre study.
Ebert W; Dienemann H; Fateh-Moghadam A; Scheulen M; Konietzko N; Schleich T; Bombardieri E
Eur J Clin Chem Clin Biochem; 1994 Mar; 32(3):189-99. PubMed ID: 7518259
[TBL] [Abstract][Full Text] [Related]
23. Comparison of cytokeratin fragment 19 (CYFRA 21-1), tissue polypeptide antigen (TPA) and carcinoembryonic antigen (CEA) as tumour markers in bronchogenic carcinoma.
Huang MS; Jong SB; Tsai MS; Lin MS; Chong IW; Lin HC; Hwang JJ
Respir Med; 1997 Mar; 91(3):135-42. PubMed ID: 9135852
[TBL] [Abstract][Full Text] [Related]
24. The Validity of Using Human Squamous Cell Carcinoma Associated Antigen and Cytokeratin 19 Fragment Antigen 21-1 to Predict Postoperative Adjuvant Radiotherapy for Nonbulky Early-Stage Squamous Cell Carcinoma of the Cervix.
Liu CZ; Zeng HX; Zhao JJ; Rong Y; Mo ZL; Li LA; Zhang JQ
Int J Gynecol Cancer; 2017 Jun; 27(5):994-1000. PubMed ID: 28498239
[TBL] [Abstract][Full Text] [Related]
25. The assessment of the prognostic value of tumor markers and cytokines as SCCAg, CYFRA 21.1, IL-6, VEGF and sTNF receptors in patients with squamous cell cervical cancer, particularly with early stage of the disease.
Kotowicz B; Fuksiewicz M; Jonska-Gmyrek J; Bidzinski M; Kowalska M
Tumour Biol; 2016 Jan; 37(1):1271-8. PubMed ID: 26289850
[TBL] [Abstract][Full Text] [Related]
26. Prognostic value of serum C-reactive protein (CRP) and cytokeratin 19 fragments (Cyfra 21-1) but not carcinoembryonic antigen (CEA) in surgically treated patients with non-small cell lung cancer.
Szturmowicz M; Rudziński P; Kacprzak A; Langfort R; Bestry I; Broniarek-Samson B; Orłowski T
Pneumonol Alergol Pol; 2014; 82(5):422-9. PubMed ID: 25133810
[TBL] [Abstract][Full Text] [Related]
27. Comparison of CYFRA 21-1 and squamous cell carcinoma antigen in detecting nasopharyngeal carcinoma.
Lee JK; Hsieh JF; Tsai SC; Ho YJ; Sun SS; Kao CH
Ann Otol Rhinol Laryngol; 2001 Aug; 110(8):775-8. PubMed ID: 11510737
[TBL] [Abstract][Full Text] [Related]
28. Additional diagnostic value of tumor markers in cytological fluid for diagnosis of non-small-cell lung cancer.
Hur J; Lee HJ; Nam JE; Kim YJ; Hong YJ; Kim HY; Kim SK; Chang J; Kim JH; Chung KY; Lee HS; Choi BW
BMC Cancer; 2012 Sep; 12():392. PubMed ID: 22954172
[TBL] [Abstract][Full Text] [Related]
29. Prognostic impact of cytological fluid tumor markers in non-small cell lung cancer.
Cho A; Hur J; Hong YJ; Lee HJ; Kim YJ; Hong SR; Suh YJ; Im DJ; Kim YJ; Lee JS; Shim HS; Choi BW
Tumour Biol; 2016 Mar; 37(3):3205-13. PubMed ID: 26432331
[TBL] [Abstract][Full Text] [Related]
30. IMP3 Immunohistochemical Expression in Inverted Papilloma and Inverted Papilloma-Associated Sinonasal Squamous Cell Carcinoma.
Hakim SA; Abd Raboh NM; Shash LS
Anal Cell Pathol (Amst); 2021; 2021():6639834. PubMed ID: 33680717
[TBL] [Abstract][Full Text] [Related]
31. Squamous cell carcinoma antigen as a diagnostic marker of nasal inverted papilloma.
Yamashita Y; Uehara T; Hasegawa M; Deng Z; Matayoshi S; Kiyuna A; Kondo S; Maeda H; Ganaha A; Suzuki M
Am J Rhinol Allergy; 2016; 30(2):122-7. PubMed ID: 26877539
[TBL] [Abstract][Full Text] [Related]
32. Elevated serum CYFRA 21-1 level as a diagnostic marker for thymic carcinoma.
Shiiya H; Ujiie H; Hida Y; Kato T; Kaga K; Wakasa S; Kikuchi E; Shinagawa N; Okada K; Ito YM; Matsuno Y
Thorac Cancer; 2021 Nov; 12(21):2933-2942. PubMed ID: 34581013
[TBL] [Abstract][Full Text] [Related]
33. Loss of p16 expression is a risk factor for recurrence in sinonasal inverted papilloma.
Menendez M; Cabal VN; Vivanco B; Suarez-Fernandez L; Lopez F; Llorente JL; Hermsen MA; Alvarez-Marcos C
Rhinology; 2022 Dec; 60(6):453-461. PubMed ID: 36173184
[TBL] [Abstract][Full Text] [Related]
34. Triple test with tumor markers CYFRA 21.1, HE4, and ProGRP might contribute to diagnosis and subtyping of lung cancer.
Korkmaz ET; Koksal D; Aksu F; Dikmen ZG; Icen D; Maden E; Onder S; Akbiyik F; Emri S
Clin Biochem; 2018 Aug; 58():15-19. PubMed ID: 29729229
[TBL] [Abstract][Full Text] [Related]
35. CYFRA 21-1 enzyme-linked immunosorbent assay. Evaluation as a tumor marker in non-small cell lung cancer.
Lai RS; Hsu HK; Lu JY; Ger LP; Lai NS
Chest; 1996 Apr; 109(4):995-1000. PubMed ID: 8635383
[TBL] [Abstract][Full Text] [Related]
36. Prognostic Roles of SCC Antigen, CRP and CYFRA 21-1 in Oral Cavity Squamous Cell Carcinoma.
DE Paz D; Young CK; Chien HT; Tsao CK; Fok CC; Fan KH; Liao CT; Wang HM; Kang CJ; Chang JT; Huang SF
Anticancer Res; 2019 Apr; 39(4):2025-2033. PubMed ID: 30952746
[TBL] [Abstract][Full Text] [Related]
37. Detection of serum Cyfra 21-1 in patients with primary oral squamous cell carcinoma.
Zhong LP; Zhu HG; Zhang CP; Chen WT; Zhang ZY
Int J Oral Maxillofac Surg; 2007 Mar; 36(3):230-4. PubMed ID: 16965897
[TBL] [Abstract][Full Text] [Related]
38. CYFRA 21-1: a suitable tumor marker in patients with head and neck cutaneous squamous cell carcinoma?
Rudhart SA; Schultz JD; Gehrt F; Pavel FL; Birk R; Hoch M; Stuck BA; Hoch S
Eur Arch Otorhinolaryngol; 2019 Dec; 276(12):3467-3475. PubMed ID: 31482332
[TBL] [Abstract][Full Text] [Related]
39. Clinical value of pretreatment serum Cyfra 21-1, tissue polypeptide antigen, and squamous cell carcinoma antigen levels in patients with cervical cancer.
Gaarenstroom KN; Bonfrer JM; Kenter GG; Korse CM; Hart AA; Trimbos JB; Helmerhorst TJ
Cancer; 1995 Sep; 76(5):807-13. PubMed ID: 8625184
[TBL] [Abstract][Full Text] [Related]
40. Correlation between EGFR gene mutation, cytologic tumor markers, 18F-FDG uptake in non-small cell lung cancer.
Cho A; Hur J; Moon YW; Hong SR; Suh YJ; Kim YJ; Im DJ; Hong YJ; Lee HJ; Kim YJ; Shim HS; Lee JS; Kim JH; Choi BW
BMC Cancer; 2016 Mar; 16():224. PubMed ID: 26979333
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
